Campylobacter Jejuni Atcc 700819: An In Silico Approach To Identify And Categorize Probable Drug Targets By Subtractive Genome Analysis

Campylobacter jejuni, the causative agent of common gastroenteritis in human, is a global public health concern. Antimicrobial resistance of this bacterium to forfluroquinolones, macrolides, tetracyclines, aminoglycosides and other antibiotics is a major challenge in controlling campylobacteriosis that led to a search for novel drug targets. For efficient remedial advancement, this experiment was aimed to identify potential drug targets of C. jejuni ATCC 700819 using computer-aided protein data analysis via subtractive genomics approach. In this study, 3 vital membrane bound unique metabolic proteins: preprotein translocase subunit SecD (T1), ccoN:cbb3-type cytochrome c oxidase subunit I (T2) and preprotein translocase subunit SecE (T3) were disclosed by analyzing 228 essential proteins of C. jejuni. Post modeling analysis excluded T3 from study sight. After analyzing the active sites and druggable pockets of these selected proteins, the highest drug scores: 0.82 and 0.81 were obtained for PO pocket of T1 and T2 respectively. In addition, protein-protein interaction study revealed other proteins including preprotein translocase subunit SecF and cbb3-type cytochrome c oxidase subunit II were highly interacted with T1 and T2 respectively. Our findings suggest that, these two important proteins might be considered as potent curative targets against C. jejuni mediated gastroenteritis.